Navigation Links
Regado Biosciences Awarded Three Grants from the Federal Government to Advance Research of Lead Programs
Date:11/3/2010

This technology is being applied to injectable antithrombotics (including anticoagulants and antiplatelet agents) in the acute and sub-acute care cardiovascular setting, a multi-billion dollar world-wide market in need of drugs with improved safety profiles and a greater degree of therapeutic control.  The products in Regado's pipeline are designed to act as optimized antithrombotics, uniquely concomitantly minimizing the risk of ischemia and bleeding, and, by allowing patient specific tuning of the desired therapeutic effect, providing a safe and unique approach to personalized medicine.

ABOUT REG1, REG2 and REG3  Regado's lead program, the anticoagulant system REG1, consists of two parenteral agents both administered by IV bolus, the first being a potent highly selective Factor IXa inhibitor (pegnivacogin, a.k.a. RB006) and the second being its complementary active control agent (anivamersen, a.k.a. RB007).  Anivamersen can be used to selectively completely or partially reverse the anticoagulant effect of pegnivacogin.  REG1, presently in a phase 2b clinical trial (the RADAR trial), is intended for application in arterial thrombosis applications, initially in Acute Coronary Syndrome patients intended for Percutaneous Coronary Intervention.  A clinical program in Open Heart Surgery [including coronary artery bypass grafting (CABG) and valve repair/replacement] is also under development.  REG2, Regado's second product candidate, consists of a subcutaneously administered depot formulation of pegnivacogin paired with the IV bolus formulation of anivamersen.  REG2 recently completed single escalating dose phase 1 clinical testing (the first successful subcutaneous application of an aptamer in humans) and is planned to be studied in a multiple escalating dose clinical trial in 2011.  It is intended for use in venous thrombosis indications such as venous thromboembolism (VTE) prophylaxis in patients undergoing abdominal s
'/>"/>

SOURCE Regado Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Regado Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference in New York City
2. Regado Biosciences to Present at the UBS Global Life Sciences Conference on September 22, 2010 in New York City
3. Regado Biosciences, Inc. Continues to Expand Its Patent Portfolio By Announcing Issuance of a New Patent for Its Product Candidates, the REG1 and REG2 Anticoagulation Systems
4. Regado Biosciences to Present at the BIO International Convention Held in Chicago, Illinois on May 5, 2010
5. Regado Biosciences to Present at the Lazard Capital Markets 6th Annual Healthcare Conference on November 17, 2009
6. Regado Biosciences to Present at the Ninth Annual Joint Symposium of BioNJ and Pennsylvania Bio on November 16, 2009
7. Regado Biosciences To Present at the 2009 Japan Biopharma Partnering Conference on October 6, 2009
8. Regado Biosciences Announces Allowance in Europe of a Fundamental Patent Broadly Covering Oligonucleotide Modulators to Blood Coagulation Factor Aptamers
9. Regado Biosciences to Present at the BioPharm America 2009 Conference on September 17, 2009
10. Regado Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2009 on September 11, 2009
11. Regado Biosciences to Present at the Rodman & Renshaw Global Investment Conference on September 10, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Calabasas, CA (PRWEB) July 10, 2014 ... academic institutions and professional associations, addressed the challenges of ... & Medical Device Industries” through strategic sourcing. Describing the ... ) with the Supply Chain Management Institute ( SCMI) ... the event on June 24 at the Kroc Institute ...
(Date:7/10/2014)... , July 10, 2014 On ... Dmitry Medvedev , presented Russia,s ... BIOCAD . The Company is developing a unique project ... project BIOCAD develops a number of innovative drugs based ... diseases. The ceremony took place at the International Exhibition ...
(Date:7/10/2014)... , July 10, 2014 /PRNewswire-iReach/ -- ... and interpretation, today announced an agreement with ... analytics for Lineagen,s NextStep Dx PLUS.  ... neurodevelopmental and neurological disorders, currently offers FirstStep ... (CMA) testing service used by healthcare providers ...
(Date:7/10/2014)... THOUSAND OAKS, Calif., July 10, 2014   Ceres, ... biotechnology and seed company, announced today financial results for ... an update on its business. Ceres reported ... progress in product performance this growing season in Brazil, ... that affected the company,s sorghum evaluation areas for part ...
Breaking Biology Technology:Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 2Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 4Dmitry Medvedev Presented BIOCAD the First National "Industry" Award 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 3Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 3Ceres Announces Fiscal Third Quarter 2014 Financial Results 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 5Ceres Announces Fiscal Third Quarter 2014 Financial Results 6Ceres Announces Fiscal Third Quarter 2014 Financial Results 7Ceres Announces Fiscal Third Quarter 2014 Financial Results 8Ceres Announces Fiscal Third Quarter 2014 Financial Results 9
... genetics,(Nasdaq: DCGN ) today expressed its enthusiastic ... bill that, many years in the,making, is now ... be signed,promptly by President Bush. GINA would provide ... prohibiting discrimination against,individuals in matters of employment or ...
... April 25 Beckman,Coulter, Inc. (NYSE: BEC ... a quarterly dividend payout of seventeen cents ($0.17) ... 23, 2008 to all stockholders of,record on May ... payout of dividends., (Logo: http://www.newscom.com/cgi-bin/prnh/20031202/BECLOGO ), ...
... BERLIN, April 25 Processes and products based ... the chemical industry in a wide range of ... the field of industrial,biotechnology in Germany will be ... Bioprocessing (April 27-30, 2008) in Chicago, Illinois.,The panel ...
Cached Biology Technology:deCODE Lauds Federal Legislation to Ban Discrimination on the Basis of Genetic Information 2deCODE Lauds Federal Legislation to Ban Discrimination on the Basis of Genetic Information 3deCODE Lauds Federal Legislation to Ban Discrimination on the Basis of Genetic Information 4World Congress on Industrial Biotechnology: Germany Home to Top Biotech Research and Investment 2
(Date:7/10/2014)... , July 9, 2014 The widespread ... in large part by meaningful use and related ... providers interact with laboratory information. Now, more than ... field of clinical informatics in order to deliver ... To address the educational needs of pathologists in ...
(Date:7/10/2014)... vegetable oil found in your popcorn or soap might not ... even worse, according to an analysis in the Cell Press ... growing demand for vegetable oil has already led to the ... trouble for orangutans in particular. If guidelines are not put ... large-scale industrial plantations from Asia into Africa will be bad ...
(Date:7/10/2014)... The Marshall Institute for Interdisciplinary Research (MIIR) ... of Medicine today announced they will be partnering ... anti-cancer drugs. , Under the agreement with Shanghai-based ... share the costs and risks of discovery and ... jointly own any intellectual property and commercialization rights ...
Breaking Biology News(10 mins):New Clinical Informatics Curriculum Prepares Future Pathologists 2New Clinical Informatics Curriculum Prepares Future Pathologists 3New Clinical Informatics Curriculum Prepares Future Pathologists 4Hunger for vegetable oil means trouble for Africa's great apes 2Marshall University to partner with international company in drug development venture 2
... record of oxygen concentration in the earth's atmosphere shows that ... gave mammals the evolutionary boost they needed to dominate the ... and lead author of a paper published Sept. 30 ... have measured the abundance of carbon 13, a byproduct ...
... have learned how to selectively shut down a flyweight-sized ... that may help doctors better understand cancer, birth defects ... be reported this week in the online Proceedings of ... of genetic material called microRNAs. , Once thought to ...
... A team of researchers from the Department of Biochemistry ... the Universitat Autònoma de Barcelona has discovered that tetanus ... a therapy against psychological disorders such as depression, anxiety ... disorders such as Parkinson's disease. , Tetanus toxin is ...
Cached Biology News:Oxygen increase caused mammals to triumph, researchers say 2Micro-molecule plays big role in birth defects 2Tetanus toxin found to have therapeutic properties 2
TXNL2 Antibody...
Rat polyclonal to Vitamin B3 ( Abpromise for all tested applications). Antigen: Chemical / Small Molecule, Vitamin B3 conjugated to BSA....
Rabbit polyclonal to CAMK 1D beta ( Abpromise for all tested applications). entrezGeneID: 57118 SwissProtID: Q5SQQ7...
Rabbit polyclonal to pCrosstide (HRP) ( Abpromise for all tested applications)....
Biology Products: